Long non‑coding RNA USP30‑AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA‑299‑3p and thereby overexpressing PTP4A1
- Mengyue Chen
- Yugang Chi
- Hongwei Chen
- Limei Zhao
Affiliations: Department of Gynaecology, The First People's Hospital of Chongqing Liangjiang New Area, Chongqing 401120, P.R. China, Department of Gynaecology and Obstetrics, Chongqing Health Center for Women and Children, Chongqing 400021, P.R. China
- Published online on: April 29, 2021 https://doi.org/10.3892/ol.2021.12766
Copyright: © Chen
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
USP30 antisense RNA 1 (USP30‑AS1) has been studied in bladder urothelial carcinoma. However, the detailed role of USP30‑AS1 in cervical cancer remains to be elucidated. Therefore, the present study determined whether USP30‑AS1 is implicated in cervical cancer malignancy, and investigated relevant molecular mechanisms. USP30‑AS1 expression was measured via reverse transcription‑quantitative PCR. Functional experiments, including the Cell Counting Kit‑8 assay, flow cytometry, Transwell migration and invasion assays, and mouse tumour model, were performed in order to elucidate the roles of USP30‑AS1. The target of USP30‑AS1 was predicted using bioinformatics analysis, which was further verified via RNA immunoprecipitation and luciferase reporter assays. Herein, USP30‑AS1 overexpression was detected in cervical cancer sample data from The Cancer Genome Atlas and our cohort. Patients with cervical cancer expressing high levels of USP30‑AS1 exhibited shorter overall survival than those with low USP30‑AS1 expression. In vitro and in vivo experiments revealed that USP30‑AS1 interference promoted cell apoptosis; restrained cell proliferation, migration and invasion in vitro, and hindered tumour growth in vivo. Mechanistically, USP30‑AS1 competed for microRNA‑299‑3p (miR‑299‑3p) in cervical cancer and lowered the regulatory actions of miR‑299‑3p on protein tyrosine phosphatase type IVA (PTP4A1), resulting in PTP4A1 overexpression. Furthermore, rescue experiments confirmed that miR‑299‑3p interventions or exogenous PTP4A1 could counteract the cancer‑inhibiting actions of USP30‑AS1 silencing on cervical cancer cells. In conclusion, the miR‑299‑3p/PTP4A1 axis is the downstream effector of USP30‑AS1 in cervical cancer, forming the USP30‑AS1/miR‑299‑3p/PTP4A1 pathway. This newly identified competing endogenous RNA pathway may offer a novel theoretical and experimental basis for developing promising new strategies for the targeted therapy of cervical cancer.